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Here, recent insights into iron homeostasis are highlighted. Three studies demonstrate the importance of the
IRE-IRP system for enterocytes in balancing extracellular iron demand against cellular iron requirements,
show that the hemochromatosis protein HFE exerts its iron-regulatory activity principally in hepatocytes
by modulating the production of hepcidin, and provide strong support for a proposed mechanism of tran-
scriptional regulation of hepcidin through a signaling cascade initiated by holotransferrin displacing HFE
from transferrin receptor 1.Iron is an essential tracemetal whose extracellular concentration
and stores are efficiently regulated. Systemic iron homeostasis
assures a stable milieu in which each cell regulates its iron up-
take to meet its own requirements. The system is challenged
by variable availability of iron in the diet, by occasional iron los-
ses through bleeding, and by fluctuations in the demand for
iron for erythropoiesis and other iron-requiring processes. An
overlapping regulatory mechanism acts during infection and in-
flammation to reduce the concentration of iron in extracellular
space, a response that presumably evolved to deny this essen-
tial nutrient to invading microbes.
The physiology of iron stores and flows has been known for
more than fifty years through insightful human and animal stud-
ies with iron radioisotopes. In humans, extracellular iron is des-
tined chiefly for hemoglobin synthesis, as erythrocyte hemoglo-
bin contains about 2 g of iron and about 1% of erythrocytes are
replaced every day. In the steady state, the iron for hemoglobin
synthesis is recovered from senescent erythrocytes that are
phagocytized by macrophages in the spleen and the liver. The
recycled iron binds to transferrin in blood circulation occupying
20%–40% of the available transferrin and is distributed to the
erythrocyte precursors in the bone marrow and to other iron-
consuming cells. Additional iron (0.3–0.4 g) helps store oxygen
in skeletal muscle myoglobin and catalyzes redox reactions in
iron-containing enzymes in all cells. Fluctuations in iron supply
and demand are buffered by storing a variable amount (typically
about 1 g) of iron in hepatocytes and in macrophages in both the
liver and the spleen.
Iron is efficiently conserved, so that only small amounts of it
are lost through cell shedding and minor bleeding (about 1–2
mg/day) and are replaced by the absorption of similar amounts
of iron by duodenal enterocytes. Intestinal iron absorption can in-
crease to 5–10 mg/day in response to increased erythropoietic
activity or other pathological stimuli, but physiological capacity
to increase iron excretion is very limited. The body iron balance
is thus chiefly maintained through regulated absorption of die-
tary iron, but the maintenance of stable extracellular iron con-
centrations is predominantly dependent on the regulation of
iron release from macrophage and hepatocyte stores. Both
iron excess (systemic iron overload) and iron deficiency have288 Cell Metabolism 7, April 2008 ª2008 Elsevier Inc.adverse effects that can be lethal for the organism. It has long
been appreciated that the ability of humans and other verte-
brates to maintain stable iron stores and extracellular iron con-
centrations implies a complex homeostatic network, but the mo-
lecular basis of this regulatory system began to emerge only
during the last decade.
Hepatocytes secrete the peptide hormone hepcidin, which
binds to the membrane protein ferroportin, an iron efflux channel
expressed in all iron-exporting cells. Upon binding hepcidin, fer-
roportin first undergoes cytoplasmic phosphorylation and inter-
nalization, then ubiquitination and degradation (Nemeth et al.,
2004; De Domenico et al., 2007). When hepcidin concentrations
are high, ferroportin degradation exceeds its rate of synthesis
and ferroportin is lost from cell membranes. In duodenal entero-
cytes, the loss of ferroportin decreases the delivery of dietary
iron to extracellular fluid. Without ferroportin, macrophages fail
to release iron recycled from senescent erythrocytes, and hepa-
tocytes retain stored iron. As the utilization of iron by erythropoi-
esis and other processes continues, the relatively small amount
of extracellular iron is depleted within hours, and iron concentra-
tions rapidly drop (Rivera et al., 2005). Conversely, when hepci-
din concentrations are low, ferroportin synthesis exceeds its
degradation, ferroportin reaccumulates in cell membranes, and
increased amounts of iron flow from iron-exporting cells into
the extracellular fluid.
However, this scheme is clearly a simplification. Not only is fer-
roportin controlled by the systemic iron demands communicated
by the hormone hepcidin, it is also regulated by the iron needs of
the cells that express ferroportin. This makes sense, as exces-
sive iron export in response to systemic demand could deplete
cellular iron, with severe consequences for the exporting cell.
As we and others have observed, model cell lines overexpress-
ing ferroportin die unless supplemented with abundant iron. Fer-
roportin mRNA contains an iron-regulatory element in the 50 un-
translated region (50IRE) that binds iron-regulatory proteins (IRP1
and IRP2) when intracellular iron levels are low. This interaction
should inhibit ferroportin translation, thus limiting iron export.
Conversely, divalent metal transporter 1 (DMT1), responsible
for the uptake of dietary iron by enterocytes, would be expected
to increase during cellular iron deprivation, raising the absorption
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binding of IRPs to 30IREs generally stabilizes mRNAs. The impor-
tance of cellular regulation of iron transport by the IRE-IRP inter-
action was recently tested in mice with enterocyte-specific
ablation of both IRP1 and IRP2 (Galy et al., 2008). Mice with
IRP-ablated enterocytes developed intestinal malabsorption
and died within 4 weeks of birth. DMT1 was decreased and
ferroportin increased in IRP-ablated enterocytes compared to
normal enterocytes, confirming the essential role of the IRE-IRP
interaction in balancing cellular and systemic iron demands.
The afferent arm of the iron-regulatory loop consists of themo-
lecular circuits that control hepcidin concentrations in plasma
and extracellular fluid. The main regulatory influences include
holotransferrin concentrations, hepatic iron stores, erythropoi-
etic activity in the bone marrow, inflammation, and perhaps
also hepatic hypoxia. All indications are that these factors regu-
late hepcidin concentrations primarily through transcriptional
mechanisms.
Hereditary hemochromatoses are genetic disorders in which
intestinal iron absorption is dysregulated so that it often greatly
exceeds the small losses of iron. Moreover, the release of re-
cycled iron from macrophages is also excessive, leading to
iron depletion of macrophages in the face of systemic iron over-
load. Recent studies have identified a common pathogenic
mechanism for most cases of hereditary hemochromatosis:
genes encoding hepcidin or its key regulators are disrupted,
leading to hepcidin deficiency. In rare patients, hepcidin produc-
tion is intact but autosomal dominant mutations cause resis-
tance of ferroportin to the effect of hepcidin. Identification of
genes involved in hereditary hemochromatosis in humans or its
equivalent in mice has provided key insights into normal iron ho-
meostasis. The most common mutations causing hereditary he-
mochromatosis in populations of northern European ancestry in-
volve the membrane protein HFE. Earlier models postulated that
HFE directly regulates intestinal iron absorption in enterocytes.
However, mice with enterocyte-specific disruption of Hfe have
normal iron homeostasis (Vujic´ Spasic´ et al., 2007), in contrast
to mice with hepatocyte-specific Hfe ablation, which develop
systemic iron overload (Vujic´ Spasic´ et al., 2008). Macrophage-
specific Hfe ablation also results in a normal iron phenotype.
These findings and the lack of progression of hereditary hemo-
chromatosis in human liver transplant recipients receiving nor-
mal livers support the concept that hepatocytes are the principal
cells directing systemic iron homeostasis, through the secretion
of the iron-regulatory hormone hepcidin.
The bone morphogenetic protein (BMP) pathway appears to
be the principal scaffold for hepcidin regulation, as indicated
by the loss of hepcidin expression and regulation inmicewith he-
patocyte-specific SMAD4 ablation (Wang et al., 2005) and by the
dramatic in vitro stimulation of hepcidin by BMPs (Babitt et al.,
2006; Truksa et al., 2006) as compared to any other known stim-
uli. How can this protean pathway, known to be involved in
development and in organ and tissue repair, function in iron ho-
meostasis? In hepatocytes, the BMP receptor (BMPR) is adap-
ted for iron regulation by its interaction with a coreceptor, the he-
patocyte- and myocyte-specific GPI-linked protein hemojuvelin
(Babitt et al., 2006, 2007). As revealed by the profound and se-
lective loss of hepcidin expression in hemojuvelin-deficient hu-
mans and mice, hemojuvelin is required for hepcidin expressionand normal iron regulation. Hemojuvelin binds to BMP2 and
BMP4 as well as to BMPR and facilitates BMP signaling (Babitt
et al., 2006, 2007). As indicated by studies in freshly isolatedmu-
rine hepatocytes (Lin et al., 2007), the BMP/hemojuvelin pathway
mediates hepcidin response to iron-transferrin, but this pathway
has not yet been reconstituted in any cell lines. A soluble form of
hemojuvelin, produced in the liver and skeletal muscle, acts as
a BMP2 and BMP4 antagonist suppressing hepcidin synthesis
(Lin et al., 2005, 2007; Babitt et al., 2007). A physiological role
of soluble hemojuvelin has not yet been demonstrated.
An effective iron homeostatic system requires molecules that
can sense iron concentration and communicate with the circuitry
that controls the production of hepcidin. Prominent candidates
for iron sensors include the two transferrin receptors, TfR1 and
TfR2, and the iron-dependent prolyl hydroxylases involved in
hypoxic regulation. The two transferrin receptors would be ex-
pected to sense the extracellular concentration of holotransfer-
rin, but their native affinity for holotransferrin is too high (in the
nM range) to detect changes in holotransferrin concentrations
(in the mM range) by conventional mechanisms dependent on
receptor occupancy. The effective affinity of TfR1 for holotrans-
ferrin is lowered by its interaction with the hemochromatosis-
related membrane protein HFE (Feder et al., 1998), so it is
possible that TfR1 could function as an iron sensor (rather than
a holotransferrin uptake protein) within a protein complex that
includes HFE.
The importance of the TfR1-HFE interaction for iron regulation
was demonstrated (Schmidt et al., 2008) in a recent study that in-
troduced mutations into mice to strengthen or weaken the inter-
action between HFE and TfR1. A mutation that increased the
binding of HFE to TfR1 caused hepcidin deficiency and iron over-
load and effectively mimicked mutations that caused HFE defi-
ciency. Micewith amutation that interferes with the TfR1-HFE in-
teraction or mice with increased HFE had high hepcidin and iron
deficiency. This study provides strong support for a model in
which HFE, when dissociated from TfR1, stimulates hepcidin
synthesis, perhaps by communicating with the BMP receptor
complex (Figure 1).
HFE and TfR2 also interact (Goswami and Andrews, 2006;
Chen et al., 2007), but unlike the TfR1-HFE interaction, there is
no competition by holotransferrin. In fact, both holotransferrin
and HFE stabilize TfR2 (Johnson and Enns, 2004; Robb and
Wessling-Resnick, 2004). Two siblings with a phenotypically se-
vere juvenile form of hereditary hemochromatosis were found to
have both homozygous Q317X TfR2 mutations and compound
heterozygous C282Y/H63D HFE mutations, suggesting an addi-
tive effect of HFE and TfR2 disruption (Pietrangelo et al., 2005).
Preliminary biochemical studies indicate that both HFE and
TfR2 interact with hemojuvelin (N.C. Andrews, personal commu-
nication), placing these molecules into the BMPR/BMP/hemoju-
velin complex.
Hepcidin production is suppressed by increased erythropoie-
sis in the bone marrow, allowing more hemoglobin synthesis by
increasing the delivery of iron from stores and from intestinal iron
absorption. Regulation of hepcidin by erythropoiesis is probably
mediated by one or more bone marrow-derived signals. This ef-
fect is most prominent in b-thalassemia and other dyserythro-
poietic anemias where the erythrocyte precursor compartment
is massively expanded but fails to generate enough mature cellsCell Metabolism 7, April 2008 ª2008 Elsevier Inc. 289
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a member of the BMP/TGF-b superfamily, may be one of patho-
logical suppressors of hepcidin in the setting of b-thalassemia
(Tanno et al., 2007), but it is not clear whether this molecule par-
ticipates in physiological regulation of hepcidin by erythropoietic
activity.
Recently, another component was added with the discovery
that the membrane-associated serine protease matriptase-2,
also called type II transmembrane serine protease 6 (TMPRSS6)
(E. Beutler, personal communication), may participate in hepci-
din regulation. A mutation deleting the catalytic domain of
TMPRSS6 caused increased hepcidin, anemia, and systemic
iron deficiency in mice. It remains to be seen how this molecule
interacts with the previously identified regulators of hepcidin.
Although the study of iron homeostasis is more than fifty years
old, most of the proteins involved in iron regulation have only
been discovered during the last ten years. As the recent discov-
ery of TMPRSS6 illustrates, we may not yet have all the pieces
of the puzzle, and we certainly need to learn much more about
how to fit them together. Iron homeostasis is not likely to lose its
excitement soon.
Figure 1. Hypothetical Model of Hepcidin Regulation
by Holotransferrin
Signaling by the receptor complex consisting of the BMP receptor (BMPR), its
ligand BMP2/4, and the coreceptor hemojuvelin (HJV) is stimulated by the
binding of holotransferrin (holoTf) to both transferrin receptors (TfR1 and
TfR2). The binding of holoTf to TfR1 releases HFE and the binding of holoTf
to TfR2 stabilizes TfR2, so both HFE and TfR2 can associate with the receptor
complex, which then phosphorylates R-Smad. R-Smad binds Smad4; they
translocate to the nucleus and help form a transcription complex to increase
the synthesis of hepcidin mRNA. The transmembrane serine protease
TMPRSS6 and sHJV can decrease hepcidin synthesis in vitro and in vivo,
but their physiologic roles in iron regulation are not yet known.290 Cell Metabolism 7, April 2008 ª2008 Elsevier Inc.REFERENCES
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